DOWNREGULATING INOS TO INCREASE CAR-T KILLING

Abstract

Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. As disclosed herein, anti-inflammatory macrophages suppress CAR-T cell expansion, induce death, and reduce CAR expression. Disclosed is a method for enhancing anti-tumor efficacy of immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject a nitric oxide synthase (NOS) inhibitor.

CPC Classifications